/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. OncLive® On Air
  2. S18 Ep37: Metastatic Non-Small Cell Lung Cancer 2026 UPDATE
S18 Ep37: Metastatic Non-Small Cell Lung Cancer 2026 UPDATE

S18 Ep37: Metastatic Non-Small Cell Lung Cancer 2026 UPDATE

OncLive® On Air · Sep 14, 2026

Metastatic NSCLC 2026 update: Comprehensive NGS/IHC testing is critical as new targeted therapies and chemo/IO combos redefine care pathways.

IHC Testing in NSCLC Now Mandatory for HER2 and CMET, Not Just PD-L1

While PD-L1 testing by IHC is standard, the diagnostic workup for metastatic NSCLC must now also include IHC for HER2 and CMET. This is because specific antibody-drug conjugates and other agents are now approved and tied directly to the protein expression levels identified by these tests.

S18 Ep37: Metastatic Non-Small Cell Lung Cancer 2026 UPDATE thumbnail

S18 Ep37: Metastatic Non-Small Cell Lung Cancer 2026 UPDATE

OncLive® On Air·2 months ago

KRAS G12C and NRG1 Fusions Defy the 'Target First' Lung Cancer Rule

In a landscape where identifying a driver mutation typically dictates using a targeted agent first-line, KRAS G12C and NRG1 fusions are notable exceptions. For these mutations, standard chemo-immunotherapy is the initial treatment, with targeted agents reserved for subsequent lines of therapy.

S18 Ep37: Metastatic Non-Small Cell Lung Cancer 2026 UPDATE thumbnail

S18 Ep37: Metastatic Non-Small Cell Lung Cancer 2026 UPDATE

OncLive® On Air·2 months ago

First-Line EGFR Lung Cancer Treatment Expands to Three Competing Combination Strategies

The standard first-line treatment for classical EGFR-mutated NSCLC has evolved from osimertinib monotherapy to include two combination strategies: osimertinib plus chemotherapy (FLORA2) and amivantamab plus lazertinib (MARIPOSA). This provides more aggressive options for patients with a higher disease burden or CNS metastases.

S18 Ep37: Metastatic Non-Small Cell Lung Cancer 2026 UPDATE thumbnail

S18 Ep37: Metastatic Non-Small Cell Lung Cancer 2026 UPDATE

OncLive® On Air·2 months ago

Avoid Overlapping Immunotherapy and Osimertinib in NSCLC to Reduce Pneumonitis Risk

Clinicians must avoid giving PD-1/PD-L1 immunotherapy concurrently with or immediately before the EGFR inhibitor osimertinib due to a significantly increased risk of severe pneumonitis. This is critical when EGFR mutation status is pending, urging caution before starting empiric immunotherapy.

S18 Ep37: Metastatic Non-Small Cell Lung Cancer 2026 UPDATE thumbnail

S18 Ep37: Metastatic Non-Small Cell Lung Cancer 2026 UPDATE

OncLive® On Air·2 months ago